Report results from the izencitinib Phase 2b/3 study in ulcerative colitis
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 23 Feb 2021
- Due
- 30 Sep 2021
- Delivered
- August 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Izencitinib ... Phase 2b/3 study in ulcerative colitis and Phase 2 study in Crohn's disease expected to report results, separately, in Q3 2021”
What we found
Evidence strength A What the grades mean
The company announced izencitinib Phase 2b/3 ulcerative colitis study results in August 2021, within Q3 2021, reporting that the primary endpoint was not met.
-
A Theravance Biopharma, Inc. 10-Q filed 2021-11-08
“In August 2021, the Company completed a Phase 2b/3 (RHEA) induction and maintenance study of izencitinib in ulcerative colitis and announced that the study results did not meet its primary endpoint.” ✓ confirmed on the page
-
A Theravance Biopharma, Inc. 10-K filed 2022-02-28
“In August 2021, we reported that results from our Phase 2b dose-finding induction study of izencitinib, our oral gut-selective pan-JAK inhibitor for inflammatory intestinal diseases, previously partnered with Janssen Biotech, Inc. (“Janssen”), did not meet its primary endpoint” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Izencitinib Phase 2b/3 ulcerative colitis study results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Theravance Biopharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C583107-024226 · Corrections policy